NEW YORK (GenomeWeb) – Epigenomics and BioChain today announced the Epi proColon colorectal cancer detection test has been approved for marketing by regulators in China. 

The approval from the China Food and Drug Administration follows the completion of a clinical validation study by BioChain earlier this year that found the non-invasive blood-based test detected 75 percent of all cancer cases at 97.5 percent specificity. BioChain anticipates launching the test in the next few weeks through its distribution channels. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.